This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Anderegg, T. R.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Anderegg, T. R.
Right arrow Articles by Jones, R. N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2002, p. 2662-2664, Vol. 46, No. 8
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.8.2662-2664.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vitro Evaluation of AZD2563, a Novel Oxazolidinone, against 603 Recent Staphylococcal Isolates

Tamara R. Anderegg,1 Douglas J. Biedenbach,1 and Ronald N. Jones1,2*

The JONES Group/JMI Laboratories, North Liberty, Iowa 52317,1 The Tuft's University School of Medicine, Boston, Massachusetts 021112

Received 24 October 2001/ Returned for modification 2 May 2002/ Accepted 16 May 2002

AZD2563, a novel oxazolidinone, and a selection of comparator drugs that included linezolid, erythromycin, clindamycin, quinolones, and gentamicin were tested against 384 Staphylococcus aureus (176 oxacillin-resistant S. aureus [ORSA]) and 219 coagulase-negative staphylococci (CoNS; 162 oxacillin resistant) by reference microdilution (all strains) and agar dilution (30 strains) methods. The following results were noted for AZD2563. (Note that, for comparison only, a breakpoint of <=4 µg/ml [the breakpoint of linezolid] was used for this study, although a susceptibility breakpoint for AZD2563 has not been determined.) For S. aureus, the MIC at which 50% of the isolates tested are inhibited (MIC50) was 1 µg/ml, the MIC90 was 2 µg/ml, and the percent susceptibility was 100%. For CoNS, the MIC50 was 0.5 µg/ml, the MIC90 was 1 µg/ml, and the percent susceptibility was 100%. ORSA and OR-CoNS strains were equally inhibited by AZD2563 and linezolid. AZD2563 demonstrated antistaphylococcal activity comparable to that of linezolid.

* Corresponding author. Mailing address: The JONES Group/JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317. Phone: (319) 665-3370. Fax: (319) 665-3371. E-mail: ronald-jones{at}jmilabs.com.

Antimicrobial Agents and Chemotherapy, August 2002, p. 2662-2664, Vol. 46, No. 8
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.8.2662-2664.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Yong, D., Yum, J. H., Lee, K., Chong, Y., Choi, S. H., Rhee, J. K. (2004). In Vitro Activities of DA-7867, a Novel Oxazolidinone, against Recent Clinical Isolates of Aerobic and Anaerobic Bacteria. Antimicrob. Agents Chemother. 48: 352-357 [Abstract] [Full Text]  
  • Howe, R. A., Wootton, M., Noel, A. R., Bowker, K. E., Walsh, T. R., MacGowan, A. P. (2003). Activity of AZD2563, a Novel Oxazolidinone, against Staphylococcus aureus Strains with Reduced Susceptibility to Vancomycin or Linezolid. Antimicrob. Agents Chemother. 47: 3651-3652 [Abstract] [Full Text]  
  • Kuklin, N. A., Pancari, G. D., Tobery, T. W., Cope, L., Jackson, J., Gill, C., Overbye, K., Francis, K. P., Yu, J., Montgomery, D., Anderson, A. S., McClements, W., Jansen, K. U. (2003). Real-Time Monitoring of Bacterial Infection In Vivo: Development of Bioluminescent Staphylococcal Foreign-Body and Deep-Thigh-Wound Mouse Infection Models. Antimicrob. Agents Chemother. 47: 2740-2748 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»